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AbstrAct
Objective Proton pump inhibitors (PPIs) are widely used, 
and their use is associated with increased risk of adverse 
events. However, whether PPI use is associated with 
excess risk of death is unknown. We aimed to examine 
the association between PPI use and risk of all-cause 
mortality.
Design Longitudinal observational cohort study.
Setting US Department of Veterans Affairs.
Participants Primary cohort of new users of PPI 
or histamine H2 receptor antagonists (H2 blockers) 
(n=349 312); additional cohorts included PPI versus no PPI 
(n=3 288 092) and PPI versus no PPI and no H2 blockers 
(n=2 887 030).
Main outcome measures Risk of death.
Results Over a median follow-up of 5.71 years (IQR 
5.11–6.37), PPI use was associated with increased risk of 
death compared with H2 blockers use (HR 1.25, CI 1.23 
to 1.28). Risk of death associated with PPI use was higher 
in analyses adjusted for high-dimensional propensity 
score (HR 1.16, CI 1.13 to 1.18), in two-stage residual 
inclusion estimation (HR 1.21, CI 1.16 to 1.26) and in 1:1 
time-dependent propensity score-matched cohort (HR 
1.34, CI 1.29 to 1.39). The risk of death was increased 
when considering PPI use versus no PPI (HR 1.15, CI 1.14 
to 1.15), and PPI use versus no PPI and no H2 blockers 
(HR 1.23, CI 1.22 to 1.24). Risk of death associated 
with PPI use was increased among participants without 
gastrointestinal conditions: PPI versus H2 blockers (HR 
1.24, CI 1.21 to 1.27), PPI use versus no PPI (HR 1.19, 
CI 1.18 to 1.20) and PPI use versus no PPI and no H2 
blockers (HR 1.22, CI 1.21 to 1.23). Among new PPI users, 
there was a graded association between the duration of 
exposure and the risk of death.
Conclusions The results suggest excess risk of death 
among PPI users; risk is also increased among those 
without gastrointestinal conditions and with prolonged 
duration of use. Limiting PPI use and duration to instances 
where it is medically indicated may be warranted.
InTroducTIon
Proton pump inhibitors (PPI) are widely 
prescribed and are also available for sale 
over the counter without prescription in 
several countries.1 2 Several observational 
studies suggest that PPI use is associated with 
increased risk of a number of adverse health 
outcomes.1 A number of studies have shown 
that PPI use is associated with significant 
risk of acute interstitial nephritis.3–5 Recent 
studies established an association between 
exposure to PPI and risk of chronic kidney 
disease (CKD), kidney disease progression 
and end-stage renal disease.2 6 7 Results from 
a large prospective observational German 
cohort suggest that patients receiving PPI had 
a higher risk of incident dementia.8 Several 
reports highlighted a rare but potentially 
fatal risk of hypomagnesemia among users 
of PPI.9–11 PPI use has been associated with 
increased risk of both incident and recur-
rent Clostridium difficile infections.12 Several 
observational analyses have shown that PPI 
use was also associated with increased risk 
of osteoporotic fractures, including hip and 
spine fractures.13 14 Less convincing—and to 
some extent inconsistent—evidence suggests 
a relationship between PPI use and risks of 
community-acquired pneumonia and cardio-
vascular events.15–17 Emerging—and far from 
conclusive—in vitro evidence suggests that 
PPI results in inhibition of lysosomal acid-
ification and impairment of proteostasis, 
leading to increased oxidative stress, endo-
thelial dysfunction, telomere shortening and 
accelerated senescence in human endothe-
lial cells.18 The experimental work provides a 
Strengths and limitations of this study
 ► National large-scale data from a network of 
integrated health systems.
 ► Employed a new user design and developed 
a number of analytical approaches where we 
consistently found a significant association between 
PPI exposure and risk of death.
 ► Cohort included mostly older white male US 
veterans, which may limit the generalisability.
 ► Did not include information on the cause of death.
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putative mechanistic link to explain some of the adverse 
events associated with PPI use.18
The adverse outcomes associated with PPI use are 
serious, and each is independently associated with higher 
risk of mortality. Evidence from several small cohort 
studies of older adults who were recently discharged from 
the hospital or institutionalised in long-term care facili-
ties suggests inconsistently that PPI use may be associated 
with increased risk of 1 year mortality.19–22 Whether PPI 
use is associated with excess risk of death is not known 
and has not been examined in large epidemiological 
studies spanning a sufficiently long duration of follow-up. 
We hypothesised that owing to the consistently observed 
associations between PPI use and risk of adverse health 
outcomes, PPI use is associated with excess risk of death, 
and that the risk of death would be more pronounced with 
increased duration of use. We therefore used the Depart-
ment of Veterans Affairs national databases to build a 
longitudinal cohort of incident users of acid suppression 
therapy, including PPI and histamine H2 receptor antag-
onists (H2 blockers), to examine the association between 
PPI use and risk of all-cause mortality and to determine 





Using administrative data from the US Department of 
Veterans Affairs, we identified patients who received 
an outpatient H2 blockers or PPI prescription between 
1 October 2006 and 30 September 2008 (n=1 762 908). 
In order to select new users of acid suppression therapy 
(incident user design), we excluded 1 356 948 patients 
who received any outpatient H2 blockers or PPI prescrip-
tions between 1 October 1998 and 30 September 2006. To 
account for patients’ kidney function, only patients with 
at least one outpatient serum creatinine value before the 
first acid suppression therapy prescription were selected 
in the cohort, yielding an analytic cohort of 349 312 
patients. Patients whose first acid suppression therapy was 
PPI (n=275 977) were considered to be in the PPI group 
during follow-up. Patients who received H2 blockers as 
their first acid suppression therapy (n=73 335) served 
as the reference group before they received any PPI 
prescription (see online supplementary figure 1). Within 
the reference group, those who received a PPI prescrip-
tion later (n=33 136) were considered to be in the PPI 
group from the date of their first PPI prescription until 
the end of follow-up.23 Time zero (T0) for primary cohort 
was defined as the first acid suppression therapy prescrip-
tion date.
Secondary cohorts
We additionally built two secondary cohorts to examine 
the association of PPI use and risk of death in (a) PPI 
versus no PPI users and (b) PPI versus non-users of acid 
suppression therapy. Patients with no PPI prescription 
between 1 October 1998 and 30 September 2006, and 
with at least one outpatient eGFR value before 1 October 
2006, were selected to evaluate the risk of death associated 
with PPI use versus no PPI use (n=3 288 092) (see online 
supplementary figure 2a). Patients with no PPI prescrip-
tion between 1 October 1998 and 30 September 2006, 
with no H2 blockers before the first PPI prescription and 
at least one outpatient eGFR value before 1 October 2006, 
were selected to evaluate the risk of death associated with 
PPI use versus no acid suppression therapy (n=2 887 030) 
(se online supplementary figure 2b). T0 for secondary 
cohorts was defined as 1 October 2006.
Patients in both primary and secondary cohorts were 
followed until 30 September 2013 or death. The study 
was approved by the Institutional Review Board of the VA 
Saint Louis Health Care System, Saint Louis, Missouri.
daTa sources
We used the Department of Veterans Affairs databases, 
including inpatient and outpatient medical SAS data 
sets (that include utilisation of data related to all inpa-
tient and outpatient encounters within the VA system), 
to ascertain detailed patient demographic character-
istics and comorbidity information based on inpatient 
and outpatient encounters.2 24 The VA Managerial Cost 
Accounting System Laboratory Results (a comprehen-
sive database that includes VA-wide results for selected 
laboratory tests obtained in the clinical setting) provided 
information on outpatient and inpatient laboratory 
results. The VA Corporate Data Warehouse Production 
Outpatient Pharmacy domain provided information on 
outpatient prescriptions. The VA Vital Status and Bene-
ficiary Identification Records Locator Subsystem files 
provided demographic characteristics and death.
Primary predictor variable
PPI use was the primary predictor. Once cohort partici-
pants received PPI prescription, they were considered with 
the effect of PPI until the end of follow-up. Medications 
that contain esomeprazole, lansoprazole, omeprazole, 
pantoprazole or rabeprazole were counted as PPI. Medi-
cations including ranitidine, cimetidine and famotidine 
were counted as H2 blockers.
outcome
The primary outcome in survival analyses was time to 
death. Death information is routinely collected by the 
Veterans Benefit Administration for all United States 
Veterans.
covariates
Covariates included age, race, gender, eGFR, number of 
outpatient serum creatinine measurements, number of 
hospitalisations, diabetes mellitus, hypertension, cardio-
vascular disease, peripheral artery disease, cerebrovascular 
disease, chronic lung disease, cancer, hepatitis C, HIV, 
dementia and diseases associated with acid suppression 
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therapy use such as gastro-oesophageal reflux disease 
(GERD), upper gastrointestinal (GI) tract bleeding, ulcer 
disease, Helicobacter pylori infection, Barrett’s oesophagus, 
achalasia, stricture and oesophageal adenocarcinoma.25–28 
eGFR was calculated using the abbreviated four-variable 
CKD epidemiology collaboration equation based on 
age, sex, race and outpatient serum creatinine.29 Race/
ethnicity was categorised as white, black or other (Latino, 
Asian, Native American or other racial/ethnic minority 
groups). Comorbidities except for hepatitis C and HIV 
were assigned on the basis of relevant ICD-9-CM (the 
International Classification of Diseases, Ninth Revision, 
Clinical Modification) diagnostic and procedure codes 
and Current Procedural Terminology (CPT) codes in the 
VA Medical SAS data sets.2 30–33 Hepatitis C and HIV were 
assigned based on laboratory results.
Baseline covariates were ascertained from 1 October 
1998 till T0. All covariates except for age, race and gender 
covariates values were treated as time-varying covariates 
where they were additionally assessed until the date of the 
first PPI prescription in those patients who did not have 
PPI prescription at T0. Any comorbidity occurring during 
the assessment period was considered present during the 
remaining follow-up. eGFR was the outpatient eGFR value 
within and most proximate to the end of the assessment 
period. Number of outpatient serum creatinine measure-
ments and number of hospitalisations were accumulated 
during the assessment period.
statistical analysis
Means, SD and t-tests are presented for normally distrib-
uted continuous variables; medians, interquartile ranges 
and Wilcoxon-Mann-Whitney tests are presented for 
non-normally distributed continuous variables; and 
counts, percentages and χ2 tests are presented for cate-
gorical variables. Incident rates per 100 person-years were 
computed for death, and CIs were estimated based on the 
normal distribution. The Simon and Makuch method for 
survival curves was used for time-dependent covariates.34
Cox regression models with time-dependent covariates 
were used in the assessment of the association between 
PPI exposure and risk of death where patients could 
switch from H2 blockers to PPI in the models. In order to 
account for potential delayed effect of PPI, patients were 
considered to have the effect of PPI from the first PPI 
prescription till the end of follow-up. In addition, time-de-
pendent Cox models were conducted in subgroups where 
patients had no GI conditions and where patients had 
no GI conditions except for GERD and in the secondary 
cohorts.
Because exposure in this observational cohort is time 
dependent, we undertook 1:1 propensity score matching 
for the primary cohort where time-dependent propen-
sity scores were calculated based on time-dependent 
Cox regression with all covariates35 (details are provided 
in online supplementary methods). After matching, all 
covariates except for age had an absolute standardised 
difference of less than 0.1, which indicated that all 
covariates except age were well balanced. Age had a 
standardised difference equal to 0.13. Doubly robust esti-
mation was applied after matching, where all covariates 
were additionally controlled for in the model to obtain an 
unbiased effect estimator.36
In order to optimise control of confounding, we 
additionally built high-dimensional propensity score-ad-
justed survival models following the multistep algorithm 
described by Schneeweiss et al37 (details are provided 
in online supplementary methods). We also applied a 
two-stage residual inclusion estimation based on instru-
mental variable approach (see online supplementary 
methods)38
In addition, we evaluated the association between dura-
tion of PPI prescription and risk of death among new 
users of PPI. Duration was defined in cumulative days of 
use and categorised as ≤30, 31–90, 91–180, 181–360 and 
361–720, where ≤30 days was considered as the refer-
ence group. To avoid immortal time bias (by definition, 
cohort participants must be alive to receive prescrip-
tion hence introducing a bias commonly referred to as 
immortal time bias), time of cohort entry was defined 
as the date of last PPI prescription plus days’ supply.39 40 
In order to ensure sufficient length of follow-up time 
following T0, we excluded cohort participants with 
cumulative duration of exposure exceeding 720 days 
(because of limited overall cohort timeline, and because 
T0 starts at the end of last prescription, those with long 
exposure will necessarily have limited follow-up time). 
In regression analyses, a 95% CI of an HR that does not 
include unity was considered statistically significant. All 
analyses were performed using SAS Enterprise Guide 
version 7.1.
sensitivity analyses
In order to further evaluate the consistency and robust-
ness of study findings, we examined the observed 
associations in a less contemporary cohort (dating back 
to an era where PPI prescription and use were far less 
frequent) of patients without acid suppression therapy 
prescriptions between 1 October 1998 and 30 September 
2000 (washout period) and with acid suppression therapy 
prescription between 1 October 2000 and 30 September 
2002 and at least one outpatient serum creatinine value 
before that. Patients in this cohort were followed till 
30 September 2007 or death. To examine the impact 
of potential residual confounding on study results, we 
conducted additional sensitivity analyses as described by 
Schneeweiss41: (a) we used the rule-out approach to iden-
tify the strength of the residual confounding that could 
fully explain the association observed in primary analyses, 
and (b) we applied an external adjustment approach 
using external information (prevalence and risk esti-
mates from published literature) to evaluate potential net 
confounding bias due to unmeasured confounders.2 41–44 
Methods are described elegantly by Schneeweiss.41 In 
addition, to remove death events that were less likely to be 
related to PPI exposure, we excluded cohort participants 
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who died within 90 days after the first PPI or H2 blocker 
prescription.
We conducted analyses based on a three-level classifica-
tion of exposure, where patient’s status at time t could be 
current use (using PPI or finished last PPI prescription 
within 90 days before t), past use (used PPI after T0 but 
finished more than 90 days before t) and never use. We 
conducted additional sensitivity analyses, which included 
haemoglobin as a covariate in cohort participants with 
available data. We also undertook analyses that stratified 
the cohort based on cardiovascular disease, history of 
pneumonia, CKD (eGFR <60 and ≥60 mL/min/1.73 m2) 
or age (<65 and ≥65 years old) at T0. Finally, and in order 
to ascertain the specificity of the findings, we examined 
the association between PPI exposure and the risk of a 
motor vehicle accident as a tracer outcome where a priori 
knowledge suggests an association is not likely to exist.
Patient involvement
No patients were involved in developing the hypothesis, 
the specific aims or the research questions, nor were 
they involved in developing plans for design or imple-
mentation of the study. No patients were involved in the 
interpretation of study results or write up of the manu-
script. There are no plans to disseminate the results of 
the research to study participants or the relevant patient 
community.
resulTs
The demographic and health characteristics of the overall 
primary cohort of new users of acid suppression therapy 
(n=349 312), by type of acid suppressant drug at time 
of cohort entry (H2 blockers n=73 335; PPI n=275 977), 
and those who were ever exposed to PPI (n=309 113) are 
provided in table 1. There were significant baseline differ-
ences in that cohort participants who were treated with 
PPI were older and were more likely to have comorbid 
conditions, including diabetes, hypertension, cardiovas-
cular disease and hyperlipidaemia. Cohort participants 
treated with PPI were also more likely to have upper GI 
tract bleeding, ulcer disease, H. pylori infection, Barrett’s 
oesophagus, achalasia, stricture and oesophageal adeno-
carcinoma (table 1). Survival curves for PPI and H2 
blockers are presented in figure 1.
association between PPI use and risk of death
Among new users of acid suppression therapy (n=349 312), 
and over a median follow-up of 5.71 years (IQR 5.11–
6.37), where exposure was treated as a time-dependent 
covariate, PPI use was associated with increased risk of 
death compared with H2 blockers use (HR 1.25, CI 1.23 
to 1.28) (table 2). Among new users of acid suppression 
therapy (n=3 49 312), in high-dimensional propensity 
score-adjusted models, new PPI users had increased risk 
of death compared with new users of H2 blockers (HR 
1.16, CI 1.13 to 1.18); based on two-stage residual inclu-
sion estimation, risk of death was higher in new PPI users 
when compared with new users of H2 blockers (HR 1.21, 
CI 1.16 to 1.26). In a 1:1 time-dependent propensity score-
matched cohort of new users of PPI and H2 blockers 
(n=1 46 670), PPI users had significantly increased risk of 
death (HR 1.34, CI 1.29 to 1.39).
We examined the relationship of PPI and risk of death 
in secondary cohorts (as described in the Methods 
section) where we considered risk associated with PPI 
use versus no known exposure to PPI (no PPI use ±H2 
blockers use) (n=3 288 092); the results suggest that PPI 
use was associated with increased risk of death (HR 1.15, 
CI 1.14 to 1.15) (table 2). Assessment of risk of death asso-
ciated with PPI use versus no known exposure to any acid 
suppression therapy (no PPI use and no H2 blockers use) 
(n=2 887 070) suggests increased risk of death with PPI 
use (HR 1.23, CI 1.22 to 1.24).
association between PPI use and risk of death in those 
without GI conditions
We then analysed the association between PPI use and risk 
of death in cohort where we excluded participants with 
documented medical conditions generally considered 
as indications for treatment with PPI, including GERD, 
upper GI tract bleeding, ulcer disease, H. pylori infection, 
Barrett’s oesophagus, achalasia, stricture and oesopha-
geal adenocarcinoma. The intent of this analysis was to 
examine the putative association of PPI use and risk of 
death in a lower risk cohort. Examination of risk of death 
associated with use of acid suppression therapy (PPI vs H2 
blockers) suggests that risk of death was increased with 
PPI use (HR 1.24, CI 1.21 to 1.27) (table 2). Examina-
tion of the risk of death associated with PPI use versus no 
known exposure to PPI (no PPI use ±H2 blockers use) 
suggests a higher risk of death associated with PPI use 
(HR 1.19, CI 1.18 to 1.20). Results were consistent where 
we examined risk of death associated with PPI use versus 
no known exposure to any acid suppression therapy (no 
PPI use and no H2 blockers use) (HR 1.22, CI 1.21 to 
1.23). Risk of death associated with PPI use in cohort 
participants without GI conditions but included partic-
ipants with GERD yielded consistent results (PPI vs H2 
blockers (HR 1.24, CI 1.21 to 1.27); PPI vs no PPI (HR 
1.14, CI 1.13 to 1.14); PPI vs no PPI and no H2 blockers 
(HR 1.22, CI 1.21 to 1.22)) (table 2).
duration of exposure and excess risk of death
We examined the association between duration of PPI 
exposure and risk of death among new users of PPI 
(n=166 098). Compared with those exposed for ≤30 days, 
there was a graded association between duration of expo-
sure and risk of death among those exposed for 31–90, 
91–180, 181–360 and 361–720 days (table 3, figure 2).
sensITIvITy analyses
We tested the robustness of study results in sensitivity 
analyses where we built a less contemporary cohort as 
described in the Methods section; demographic and 
health characteristics of this cohort are provided in online 
supplementary table 1. Where exposure was treated as 
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time dependent, PPI use was associated with increased 
risk of death compared with H2 blockers use (HR 1.17, 
CI 1.15 to 1.19). In a 1:1 time-dependent propensity 
score-matched cohort of PPI and H2 blockers, PPI users 
had significantly increased risk of death HR 1.21 (CI 1.19 
to 1.24). Furthermore, we also observed a graded asso-
ciation between cumulative duration of exposure to PPI 
and risk of death (see online supplementary table 2 and 
online supplementary figure 3).
To examine the potential impact of residual 
confounding on study results, we used rule-out and 
external adjustment approaches as described by Schnee-
weiss.41 Using the rule-out approach, we characterised 
a set of parameters (OR for relationship of PPI and 
confounder and HR for relationship of confounder 
and death) with sufficient strength to fully explain the 
association observed in primary analyses (see online 
supplementary figure 4). For example, if the confounder 
was two times as likely among PPI users (OR=2), and the 
HR of death associated with the uncontrolled confounder 
exceeded 4.0, then the uncontrolled confounder would 
fully explain the observed association between PPI and 
death (see online supplementary figure 4). Given that 
our analyses accounted for most known strong inde-
pendent risk factors of death and employed an active 
comparator group, to cancel the results, any uncontrolled 
confounder of the required prevalence (OR 2 or more in 
the example above) and strength (HR 4 or more in the 
example above) would also have to be independent of the 
confounders already adjusted for and is unlikely to exist; 
thus, the results cannot be fully explained by this putative 
uncontrolled confounder.
External adjustment to estimate the impact of three 
unmeasured confounders, including obesity, smoking 
and use of therapeutics including anticoagulants, anti-
platelet agents and non-steroidal anti-inflammatory 
drugs, shows a net confounding bias of 9.66% (see online 
supplementary figure 5). The total bias could move a null 
association between PPI and death from HR 1.00 to HR 
















































































































































































































































































































































































































































































































































































Figure 1 Survival curves for PPI and H2 blockers. PPI, 
proton pump inhibitor.
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Table 2 Association between PPI use and risk of death
Association between PPI and death Reference PPI use
PPI use vs H2 blockers use
(n=3 49 312)
Incident rate (95% CI) 3.32 (3.25 to 3.39) 4.67 (4.64 to 4.71)
Unadjusted HR (95% CI) 1 1.46 (1.43 to 1.49)
Adjusted HR (95% CI) 1 1.25 (1.23 to 1.28)
High-dimensional propensity score-adjusted 
model of new users of PPI vs H2 blockers
(n=3 49 312)
Incident rate (95% CI) 3.32 (3.25 to 3.39) 4.74 (4.70 to 4.77)
HR (95% CI) 1 1.16 (1.13 to 1.18)
Two-stage residual inclusion estimation model 
of new users of PPI vs H2 blockers
(n=3 18 960)
Incident rate (95% CI) 3.32 (3.25 to 3.39) 4.74 (4.70 to 4.77)
HR (95% CI) 1 1.21 (1.16 to 1.26)
Time-dependent propensity score-matched 
PPI vs H2 blockers
(n=1 46 670)
Incident rate (95% CI) 3.32 (3.25 to 3.39) 4.37 (4.30 to 4.44)
Unadjusted HR (95% CI) 1 1.38 (1.34 to 1.42)
Adjusted HR (95% CI) 1 1.34 (1.29 to 1.39)
PPI use vs no PPI
(n=3 288 092)
Incident rate (95% CI) 3.64 (3.63 to 3.65) 5.50 (5.47 to 5.53)
Unadjusted HR (95% CI) 1 1.47 (1.46 to 1.48)
Adjusted HR (95% CI) 1 1.15 (1.14 to 1.15)
PPI use vs no PPI or H2 blockers
(n=2 886 879)
Incident rate (95% CI) 3.47 (3.46 to 3.48) 5.50 (5.47 to 5.53)
Unadjusted HR (95% CI) 1 1.53 (1.52 to 1.54)
Adjusted HR (95% CI) 1 1.23 (1.22 to 1.24)
PPI vs H2 blockers in a cohort without GI 
conditions
(n=2 14 521)
Incident rate (95% CI) 3.80 (3.71 to 3.89) 5.39 (5.34 to 5.44)
Unadjusted HR (95% CI) 1 1.47 (1.43 to 1.51)
Adjusted HR (95% CI) 1 1.24 (1.21 to 1.27)
PPI vs no PPI in a cohort without GI conditions
(n=2 790 697)
Incident rate (95% CI) 3.54 (3.53 to 3.55) 5.89 (5.86 to 5.93)
Unadjusted HR (95% CI) 1 1.62 (1.61 to 1.63)
Adjusted HR (95% CI) 1 1.19 (1.18 to 1.20)
PPI vs no PPI or H2 blockers in a cohort 
without GI conditions
(n=2 543 480)
Incident rate (95% CI) 3.45 (3.44 to 3.46) 5.89 (5.86 to 5.93)
Unadjusted HR (95% CI) 1 1.65 (1.64 to 1.67)
Adjusted HR (95% CI) 1 1.22 (1.21 to 1.23)
PPI vs H2 blockers in a cohort without GI 
conditions except for GERD
(n=311 115)
Incident rate (95% CI) 3.30 (3.23 to 3.37) 4.51 (4.47 to 4.54)
Unadjusted HR (95% CI) 1 1.42 (1.38 to 1.45)
Adjusted HR (95% CI) 1 1.24 (1.21 to 1.27)
PPI vs no PPI in a cohort without GI conditions 
except for GERD
(n=3 132 126)
Incident rate (95% CI) 3.59
(3.58 to 3.60)
5.36 (5.34 to 5.39)
Unadjusted HR (95% CI) 1 1.45 (1.44 to 1.46)
Adjusted HR (95% CI) 1 1.14 (1.13 to 1.14)
PPI vs no PPI or H2 blockers in a cohort 
without GI conditions except for GERD
(n=2 678 478)
Incident rate (95% CI) 3.44 (3.44 to 3.45) 5.36 (5.34 to 5.39)
Unadjusted HR (95% CI) 1 1.50 (1.49 to 1.51)
Adjusted HR (95% CI) 1 1.22 (1.21 to 1.22)
Incident rate as incident death in 100 person-years. 
All models except time-dependent propensity score-matched and high-dimensional propensity score-adjusted models were time-dependent 
models. Effect of PPI was treated as time dependent and was defined as once patients used PPI, they were in PPI group during the remaining 
follow-up.
Adjusted model controlling for eGFR, age, race, gender, number of serum creatinine measurements, number of hospitalisations, diabetes 
mellitus, hypertension, cardiovascular disease, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, 
HIV, dementia, cancer, GERD, upper GI tract bleeding, ulcer disease, H. pylori infection, Barrett’s oesophagus, achalasia, stricture and 
oesophageal adenocarcinoma, unless used in analysis inclusion criteria.
GI conditions include upper GI tract bleeding, ulcer disease, H. pylori infection, Barrett’s oesophagus, achalasia, stricture and oesophageal 
adenocarcinoma.
GERD, gastro-oesophageal reflux disease; GI, gastrointestinal; PPI, proton pump inhibitor.
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to 10.0%). The association we observed between PPI and 
death was 1.25>1.10, which cannot be fully due to bias of 
unmeasured confounding.
In analyses where time-dependent exposure was classi-
fied as current use (within 90 days), past use (use prior 
to 90 days) and never use of PPI, compared with use of 
H2 blockers and never use of PPI (the reference group), 
current use of PPI and past use of PPI were associated 
with increased in risk of death (HR 1.23, CI 1.21 to 1.26, 
and HR 1.53, CI 1.50 to 1.57, respectively).
The association between PPI and death remained signif-
icant after excluding cohort participants who died within 
90 days after the first PPI or H2 blocker prescription 
(HR 1.23, CI 1.20 to 1.26), or additionally controlling for 
haemoglobin levels (HR 1.25, CI 1.23 to 1.28). In models 
stratified for the presence of cardiovascular disease, 
history of pneumonia, CKD and age at T0, there was 
increased risk of death associated with PPI use in those 
with and without cardiovascular disease (HR 1.19, CI 1.15 
to 1.23, and HR 1.30, CI 1.27 to 1.34, respectively), with 
and without history of pneumonia (HR 1.39, CI 1.32 to 
1.45, and HR 1.21, CI 1.18 to 1.24, respectively), with and 
without CKD (HR 1.18, CI 1.14 to 1.22, and HR 1.29, CI 
1.26 to 1.33, respectively) and above and below age 65 
years (HR 1.17, CI 1.13 to 1.20, and HR 1.44, CI 1.39 to 
1.50, respectively). As a test of specificity, among users of 
acid suppression therapy, PPI use was not associated with 
increased risk of the tracer outcome of a motor vehicle 
accident (HR 0.99, CI 0.89 to 1.10).
dIscussIon
This study provides insights into the excess risk of death 
associated with PPI use. In a large primary cohort of new 
users of acid suppression therapy followed for a median 
of 5.71 years, we show a significant association between 
PPI use and risk of all-cause mortality. Risk was increased 
among those with no documented medical indications 
for PPI use and with prolonged duration of use. The 
results were consistent in multiple analyses and robust 
to changes in epidemiological design and statistical spec-
ifications, and were reproduced in an earlier and less 
contemporary cohort from an era where PPI use was far 
less frequent.45
PPI are widely used by millions of people for indications 
and durations that were never tested or approved; they 
are available over the counter (without prescription) in 
several countries and generally perceived as safe class of 
therapeutics. They are often overprescribed, rarely depre-
scribed and frequently started inappropriately during a 
hospital stay, and their use extended for long-term dura-
tion without appropriate medical indication.46–50 Results 
of nationally representative data from the National 
Health and Nutrition Examination Survey, where anal-
yses were weighted to represent the US adult population, 
showed that the use of prescription PPI increased from 
3.9% to 7.8% from 1999–2000 to 2011–2012, repre-
senting a doubling of prevalence ratio.45 Studies estimate 
that between 53% and 69% of PPI prescriptions are for 
inappropriate indications46 51 where benefits of PPI use 
may not justify the risks for many users.51–53 The findings 
in our study highlight a potential excess risk of death 
among users of PPI, and in particular among cohort 
participants without GI comorbidities, and that risk is 
increased with prolonged duration of PPI exposure. 
Although our results should not deter prescription and 
use of PPI where medically indicated, they may be used to 
encourage and promote pharmacovigilance and empha-
sise the need to exercise judicious use of PPI and limit 
use and duration of therapy to instances where there is 
Table 3 Duration of exposure to PPI and risk of death among new users of PPI (n=1 66 098)
Duration (days) ≤30 31–90 91–180 181–360 361–720
N
(%)
24 748 (14.90) 39 345 (23.69) 29 334 (17.66) 33 907 (20.41) 38 764 (23.34)
HR (95% CI) 1 1.05 (1.02 to 1.08) 1.17 (1.13 to 1.20) 1.31 (1.27 to 1.34) 1.51 (1.47 to 1.56)
Within people exposed to PPI between 1 and 720 days.
Model controls for eGFR, age, race, gender, number of serum creatinine measurements, number of hospitalisations, diabetes mellitus, 
hypertension, cardiovascular disease, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia, 
cancer, GERD, upper GI tract bleeding, ulcer disease, Helicobacter pylori infection, Barrett’s oesophagus, achalasia, stricture and 
oesophageal adenocarcinoma.
Time zero defined as date when the patient's last PPI prescription ends.
GERD, gastro-oesophageal reflux disease; GI, gastrointestinal; PPI, proton pump inhibitor.
Figure 2 Duration of PPI exposure and risk of death among 
new PPI users (n=166 098). PPI, proton pump inhibitor.
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a clear medical indication and where benefit outweighs 
potential risk.1 Standardised guidelines for initiating 
PPI prescription may lead to reduced overuse,54 regular 
review of prescription and over-the-counter medications 
and deprescription where a medical indication for PPI 
treatment ceases to exist may be a meritorious approach.52
The biologic mechanism underpinning the association 
of PPI use and risk of death is not clear. Experimental 
evidence in rats suggests that PPI administration limits the 
regenerative capacity of livers following partial hepatec-
tomy.55 Administration of PPI upregulates expression of 
mRNA and protein level and results in increased activity 
of the heme oxygenase-1 enzyme in gastric and endothe-
lial cells.56 Heme oxygenase-1 is generally seen as salutary, 
but its beneficial properties are vitiated at higher doses, 
and with sustained duration of expression.57 PPI treat-
ment impairs lysosomal acidification and proteostasis 
and results in increased oxidative stress, dysfunction, telo-
mere shortening and accelerated senescence of human 
endothelial cells.18 58 Wu and collaborators undertook 
a systematic toxicity mechanism analysis using a high-
throughput in silico analysis of microarray data; they 
reported that PPI upregulated genes in the cellular 
retinol metabolism pathway and downregulated genes 
in the complement and coagulation cascades pathway, 
and that PPI may block pathways of antigen presentation 
and abrogate the synthesis and secretion of cytokines 
and complement component proteins and coagulation 
factors.58 59 How the changes in gene expression contribute 
to excess risk of death is not yet entirely clear. The plau-
sible clinical course leading to heightened risk of death is 
likely mediated by the occurrence of one or more of the 
adverse events associated with PPI use (kidney disease, 
dementia, hypomagnesemia, C. difficile infection, osteo-
porotic fracture and so on). Further studies are needed to 
characterise the biologic mechanisms that might explain 
the epidemiological findings in this report.
The constellation of findings in this report must be 
interpreted with the full cognizance of the observational 
study design where confounding by indication and selec-
tion bias may represent limitations. We employed an 
analytic strategy to evaluate the risk of death among users 
of acid suppression therapy (PPI and H2 blockers), a class 
of therapeutics generally prescribed for similar indica-
tions, a strategy that may lessen but does not completely 
eliminate the possibility of confounding by indication 
bias. We additionally built time-dependent propensity 
score-matched cohort and high-dimensional propen-
sity score-adjusted models, and we employed the use of 
instrumental variable to reduce potential confounding 
bias. Although we accounted for known covariates in our 
analyses, it is possible that there are residual confounders 
(either unmeasured or unknown) that may still confound 
the association of PPI and risk of death. However, we 
evaluated the impact of residual confounding in quan-
titative bias analyses, and the results suggest that even 
with the application of unlikely (and exaggerated) set 
of assumptions, the risk cannot be fully explained by 
residual confounding. In our analyses, we defined drug 
exposure as having a prescription for it. Because PPIs 
(and H2 blockers) are available over the counter in 
the USA, it is possible that some patients in this cohort 
may have obtained and used PPI without prescription. 
However, owing to financial considerations, this is not 
highly likely, and if it occurred in some patients, it will 
have biased the results against the primary hypothesis and 
resulted in underestimation of risk. The cohort included 
mostly older white male US veterans, which may limit the 
generalisability of study results to a broader population. 
Our data sets did not include information on the cause 
of death. The study has a number of strengths, including 
the use of national large-scale data from a network of 
integrated health systems, which were captured during 
routine medical care that minimises selection bias. We 
employed a new user (incident user) approach and eval-
uated the association between PPI use and risk of death 
using a number of analytical approaches where we consis-
tently found a significant association between PPI use and 
increased risk of death. The consistency of study findings 
in our report and the growing body of evidence in the 
literature showing a host of adverse events associated with 
PPI use are compelling, and because of the high preva-
lence of PPI use, it may have public health implications. 
Exercising pharmacovigilance and limiting PPI use to 
instances and durations where it is medically indicated 
may be warranted.
Author affiliations
1Clinical Epidemiology Center, Research and Education Service, VA Saint Louis 
Health Care System, Saint Louis, Missouri, USA
2Department of Medicine, Washington University School of Medicine, Saint Louis, 
Missouri, USA
3Department of Biostatistics, College for Public Health and Social Justice, Saint 
Louis University, Saint Louis, Missouri, USA
4Division of Public Health Sciences, Department of Surgery, Washington University 
School of Medicine, Saint Louis, Missouri, USA
5Renal Section, Medicine Service, VA Saint Louis Health Care System, Saint Louis, 
Missouri, USA
6Institute for Public Health, Washington University in Saint Louis, Saint Louis, 
Missouri, USA
Contributors Research area and study design: YX, BB, TL, HX, YY and ZAA; data 
acquisition: YX and BB; data analysis and interpretation: YX, BB, TL, HX, YY and 
ZAA; statistical analysis: YX and BB; supervision and mentorship: ZAA. Each author 
contributed important intellectual content during manuscript drafting or revision and 
accepts accountability for the overall work by ensuring that questions pertaining to 
the accuracy or integrity of any portion of the work are appropriately investigated 
and resolved. ZAA takes responsibility that this study has been reported honestly, 
accurately and transparently; that no important aspects of the study have been 
omitted; and that any discrepancies from the study as planned have been 
explained.
Disclaimer The contents do not represent the views of the US Department of 
Veterans Affairs or the US Government.
Competing interests None declared.
Ethics approval This research project was reviewed and approved by the 
Institutional Review Board of the VA Saint Louis Health Care System.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Data are available through the US Department of 
Veterans Affairs.
group.bmj.com on July 10, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
10 Xie Y, et al. BMJ Open 2017;7:e015735. doi:10.1136/bmjopen-2016-015735
Open Access 
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4.0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
references
 1. Schoenfeld AJ, Grady D. Adverse effects associated with proton 
pump inhibitors. JAMA Intern Med 2016;176:172–4.
 2. Xie Y, Bowe B, Li T, et al. Proton pump inhibitors and risk of incident 
CKD and progression to ESRD. J Am Soc Nephrol 2016;27:3153–63.
 3. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors 
and the risk of acute kidney injury in older patients: a population-
based cohort study. CMAJ Open 2015;3:E166–E171.
 4. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and 
acute kidney injury: a nested case-control study. BMC Nephrol 
2013;14:150.
 5. Blank ML, Parkin L, Paul C, et al. A nationwide nested case-control 
study indicates an increased risk of acute interstitial nephritis with 
proton pump inhibitor use. Kidney Int 2014;86:837–44.
 6. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor 
use and the risk of chronic kidney disease. JAMA Intern Med 
2016;176:238–46.
 7. Xie Y, Bowe B, Li T, et al. Long-term kidney outcomes among users 
of proton pump inhibitors without intervening acute kidney injury. 
Kidney Int 2017;91:1482–94.
 8. Gomm W, von Holt K, Thomé F, et al. Association of proton pump 
inhibitors with risk of dementia: a pharmacoepidemiological claims 
data analysis. JAMA Neurol 2016;73:410–6.
 9. Danziger J, William JH, Scott DJ, et al. Proton-pump inhibitor use is 
associated with low serum magnesium concentrations. Kidney Int 
2013;83:692–9.
 10. Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M, et al. Proton 
pump inhibitors and hypomagnesemia in the general population: a 
population-based cohort study. Am J Kidney Dis 2015;66:775–82.
 11. Broeren MA, Geerdink EA, Vader HL, et al. Hypomagnesemia 
induced by several proton-pump inhibitors. Ann Intern Med 
2009;151:755–6.
 12. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile 
infection with acid suppressing drugs and antibiotics: meta-analysis. 
Am J Gastroenterol 2012;107:1011–9.
 13. Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of 
fractures: an update meta-analysis. Osteoporos Int 2016;27:339–47.
 14. Yu EW, Bauer SR, Bain PA, et al. Proton pump inhibitors and risk 
of fractures: a meta-analysis of 11 international studies. Am J Med 
2011;124:519–26.
 15. Melloni C, Washam JB, Jones WS, et al. Conflicting results between 
randomized trials and observational studies on the impact of proton 
pump inhibitors on cardiovascular events when coadministered with 
dual antiplatelet therapy: systematic review. Circ Cardiovasc Qual 
Outcomes 2015;8:47–55.
 16. Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors 
and the risk of hospitalisation for community-acquired pneumonia: 
replicated cohort studies with meta-analysis. Gut 2014;63:552–8.
 17. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and 
risk of pneumonia: a systematic review and meta-analysis. CMAJ 
2011;183:310–9.
 18. Yepuri G, Sukhovershin R, Nazari-Shafti TZ, et al. Proton pump 
inhibitors accelerate endothelial senescence. Circ Res 2016;118.
 19. Bell JS, Strandberg TE, Teramura-Gronblad M, et al. Use of proton 
pump inhibitors and mortality among institutionalized older people. 
Arch Intern Med 2010;170:1604–5.
 20. Maggio M, Corsonello A, Ceda GP, et al. Proton pump inhibitors 
and risk of 1-year mortality and rehospitalization in older 
patients discharged from acute care hospitals. JAMA Intern Med 
2013;173:518–23.
 21. Teramura-Grönblad M, Bell JS, Pöysti MM, et al. Risk of death 
associated with use of PPIs in three cohorts of institutionalized older 
people in Finland. J Am Med Dir Assoc 2012;13:488.e9–e13.
 22. Wilson N, Gnjidic D, March L, et al. Use of PPIs are not associated 
with mortality in institutionalized older people. Arch Intern Med 
2011;171:866.
 23. Crowley J . Covariance analysis of heart transplant survival data Hu 
Marie. J Am Stat Assoc 1977;72:27–36
 24. Li T, Xie Y, Bowe B, et al. Serum phosphorus levels and risk of 
incident dementia. PLoS One 2017;12:e0171377.
 25. Gawron AJ, Pandolfino JE, Miskevics S, et al. Proton pump 
inhibitor prescriptions and subsequent use in US veterans 
diagnosed with gastroesophageal reflux disease. J Gen Intern Med 
2013;28:930–7.
 26. Bowe B, Xie Y, Xian H, et al. Low levels of high-density lipoprotein 
cholesterol increase the risk of incident kidney disease and its 
progression. Kidney Int 2016;89:886–96.
 27. Bowe B, Xie Y, Xian H, et al. High density lipoprotein cholesterol and 
the risk of all-cause mortality among U.S. veterans. Clin J Am Soc 
Nephrol 2016;11:1784–93.
 28. Bowe B, Xie Y, Xian H, et al. Geographic Variation and US County 
Characteristics Associated With Rapid Kidney Function Decline. 
Kidney International Reports 2017;2:5–17.
 29. Levey AS, Stevens LA, Schmid CH, et al. A new equation 
to estimate glomerular filtration rate. Ann Intern Med 
2009;150:604–12.
 30. Xie Y, Bowe B, Xian H, et al. Estimated GFR Trajectories of People 
Entering CKD Stage 4 and Subsequent Kidney Disease Outcomes 
and Mortality. Am J Kidney Dis 2016;68:219–28.
 31. Xie Y, Bowe B, Xian H, et al. Rate of kidney function decline and 
risk of hospitalizations in stage 3A CKD. Clin J Am Soc Nephrol 
2015;10:1946–55.
 32. Xie Y, Bowe B, Xian H, et al. Estimated GFR trajectories of people 
entering CKD Stage 4 and subsequent kidney disease outcomes and 
mortality. Am J Kidney Dis 2016;68:219–28.
 33. Xie Y, Bowe B, Xian H, et al. Renal function trajectories in patients 
with prior improved eGFR slopes and risk of death. PLoS One 
2016;11:e0149283.
 34. Schultz LR, Peterson EL, Breslau N. Graphing survival curve 
estimates for time-dependent covariates. Int J Methods Psychiatr 
Res 2002;11:68–74.
 35. Lu B. Propensity score matching with time-dependent covariates. 
Biometrics 2005;61:721–8.
 36. Funk MJ, Westreich D, Wiesen C, et al. Doubly robust estimation of 
causal effects. Am J Epidemiol 2011;173:761–7.
 37. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional 
propensity score adjustment in studies of treatment effects using 
health care claims data. Epidemiology 2009;20:512–22.
 38. Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion 
estimation: addressing endogeneity in health econometric modeling. 
J Health Econ 2008;27:531–43.
 39. Adams AL, Black MH, Zhang JL, et al. Proton-pump inhibitor use and 
hip fractures in men: a population-based case-control study. Ann 
Epidemiol 2014;24:286–90.
 40. Suissa S. Immortal time bias in observational studies of drug effects. 
Pharmacoepidemiol Drug Saf 2007;16:241–9.
 41. Schneeweiss S. Sensitivity analysis and external adjustment for 
unmeasured confounders in epidemiologic database studies of 
therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291–303.
 42. GBD 2015 Risk Factors Collaborators. Global, regional, and national 
comparative risk assessment of 79 behavioural, environmental and 
occupational, and metabolic risks or clusters of risks, 1990-2015: a 
systematic analysis for the Global Burden of Disease Study 2015. 
Lancet 2016;388:1659–724.
 43. GBD 2015 Mortality and Causes of Death Collaborators. Global, 
regional, and national life expectancy, all-cause mortality, and cause-
specific mortality for 249 causes of death, 1980-2015: a systematic 
analysis for the Global Burden of Disease Study 2015. Lancet 
2016;388:1459–544.
 44. Hvid-Jensen FNR, Pedersen L, Funch-Jensen P, et al. Thomsen RW 
Lifestyle factors among proton pump inhibitor users and nonusers: 
a cross-sectional study in a population-based setting. Dovepress 
2013;5:493–9.
 45. Kantor ED, Rehm CD, Haas JS, et al. Trends in prescription drug 
use among adults in the United States from 1999-2012. JAMA 
2015;314:1818–31.
 46. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. 
BMJ 2008;336:2–3.
 47. Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate 
prescribing of proton pump inhibitors in patients with Clostridium 
difficile-associated disease. QJM 2008;101:445–8.
 48. Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid 
suppression started inappropriately during hospitalization. Aliment 
Pharmacol Ther 2005;21:1203–9.
 49. Strid H, Simren M, Bjornsson ES. Overuse of acid suppressant 
drugs in patients with chronic renal failure. Nephrology, dialysis, 
transplantation: official publication of the European Dialysis and 
Transplant Association—European Renal Association. Nephrol Dial 
Transplant 2003;18:570–5.
group.bmj.com on July 10, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 11Xie Y, et al. BMJ Open 2017;7:e015735. doi:10.1136/bmjopen-2016-015735
Open Access
 50. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and 
over-the-counter medications and dietary supplements among older 
adults in the United States. JAMA 2008;300:2867–78.
 51. Katz MH. Failing the acid test: benefits of proton pump inhibitors 
may not justify the risks for many users. Arch Intern Med 
2010;170:747–8.
 52. Linsky A, Simon SR. Reversing gears: discontinuing medication 
therapy to prevent adverse events. JAMA Intern Med  
2013;173:524–5.
 53. Grady D, Redberg RF. Less is more: how less health care can result 
in better health. Arch Intern Med 2010;170:749–50.
 54. Yachimski PS, Farrell EA, Hunt DP, et al. Proton pump inhibitors for 
prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect 
of standardized guidelines on prescribing practice. Arch Intern Med  
2010;170:779–83.
 55. Kucuk HF, Akyol H, Kaptanoglu L, et al. Effect of proton pump 
inhibitors on hepatic regeneration. Eur Surg Res 2006;38:322–8.
 56. Becker JC, Grosser N, Waltke C, et al. Beyond gastric acid 
reduction: proton pump inhibitors induce heme oxygenase-1 in 
gastric and endothelial cells. Biochem Biophys Res Commun 
2006;345:1014–21.
 57. Nath KA. Heme oxygenase-1 and acute kidney injury. Curr Opin 
Nephrol Hypertens 2014;23:17–24.
 58. Wu D, Qiu T, Zhang Q, et al. Systematic toxicity mechanism analysis 
of proton pump inhibitors: an in Silico Study. Chem Res Toxicol 
2015;28:419–30.
 59. Liu W, Baker SS, Trinidad J, et al. Inhibition of lysosomal 
enzyme activities by proton pump inhibitors. J Gastroenterol 
2013;48:1343–52.
group.bmj.com on July 10, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
cohort study of United States veterans
Inhibitors: a longitudinal observational 
Risk of death among users of Proton Pump
Al-Aly
Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian, Yan Yan and Ziyad
doi: 10.1136/bmjopen-2016-015735
2017 7: BMJ Open 
 http://bmjopen.bmj.com/content/7/6/e015735






Supplementary material can be found at: 
References
 #BIBLhttp://bmjopen.bmj.com/content/7/6/e015735
This article cites 58 articles, 10 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections




To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on July 10, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
